Skip to content
Screener

Alumis Inc. ALMS Price / sales

Price / sales at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.4×+0.4×
Amgen logo
AmgenAMGN
5.1×+0.9×
Immunome logo
ImmunomeIMNM
616.2×+563×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
176.3×+173×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
1.9×0.0×
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
89.9×+80.1×

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%

Profitability

See full
Operating margin-5,364%—
Net margin-2,825.7%—
FCF margin-4,487.4%—

Returns & leverage

See full
Return on equity-64.6%—
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

market cap/total revenue=333.5×

Based on the most recent quarter.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010

FAQ

What is Alumis Inc.'s price / sales?
Alumis Inc. (ALMS) reported price / sales of 333.5× in Q1 2026.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.

Ask your AI about Alumis Inc.'s price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude